M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 22.03.2018 | 07:55

M1 Kliniken AG increases profit (EBT) by 36.4% in 2017: On growth track with top-class aesthetic medicine

DGAP-News: M1 Kliniken AG / Key word(s): Preliminary Results

22.03.2018 / 07:55
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG increases profit (EBT) by 36.4% in 2017: On growth track with top-class aesthetic medicine

- Preliminary figures 2017: Sales EUR 47.2 million (+31.1%), EBT EUR 7.4 million (+36.4%)
- Number of specialist centres increased from 11 to 17, alone 5 in Q4
- Positive outlook: increase in sales and profits also planned for 2018



Berlin, 22.03.2018 - On growth track with top-class aesthetic medicine: M1 Kliniken AG (ISIN: DE000A0STSQ8), the leading private provider of health services in the field of beauty medicine in Germany, has again significantly increased its sales and profits in 2017. According to unaudited figures, sales increased by 31.1% from EUR 36.0 million in 2016 to EUR 47.2 million in the previous year. The result from ordinary activities (EBT) rose by 36.4% from EUR 5.5 million in 2016 to EUR 7.4 million.

The M1 Group's growth driver is "M1 Med Beauty", the leading brand for aesthetic and plastic treatments in Germany. In 2017, the number of specialist centres in Germany increased by more than 50% from 11 to 17. The number of treatments also increased significantly from 100,000 to over 150,000. Five specialist centres - Wiesbaden, Münster, Berlin II and III and Mannheim - were opened in the fourth quarter alone. M1 has thus already created the basis for further sales and earnings growth in the current year. In addition, a second location was opened in Munich in the first weeks of 2018, and larger premises were moved into in Frankfurt. The group now operates a Germany-wide network of 19 specialist centres for beauty treatments and, with the Schlossklinik in Berlin the largest and most modern specialist clinic for plastic and aesthetic medicine in Europe.

"In 2017, we again succeeded in significantly expanding our capacities and at the same time growing profitably. We intend to continue along this path in the coming years. The potential for this is there", says Patrick Brenske. "Our specialisation is the basis for the highest quality, and we are the first in Germany to implement this consistently and successfully within the field of beauty medicine." In the further course of 2018, the M1 Group plans to open numerous new locations and begin its international expansion. In addition, the company sees great market potential in other areas of aesthetic and plastic medicine. Accordingly, the range of services offered by the specialist centres is to be expanded.

About M1 Kliniken AG
M1 Kliniken AG is the leading private provider of health care services in the field of beauty medicine in Germany. In the aesthetic and surgical field, the Group offers products and services of the highest quality standard. Under the brand name "M1 Med Beauty", a network of currently 19 specialist centres for beauty treatments and a surgical clinic is operated. With six operating theatres and 35 beds, the M1 Schlossklinik Berlin is one of the largest and most modern facilities of its kind in Europe. The Group also markets high-quality products to doctors, pharmacies and wholesalers. www.m1-kliniken.de/en

Details of the M1 Kliniken AG share
Subscribed capital: EUR 16,500,000
Class of shares: Bearer shares
ISIN: DE000A0STSQ8 * WKN: A0STSQ * Stock exchange symbol: M12

Contact
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 887 086 225
M: ir@m1-kliniken.de



22.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Über 50% Kurschance bei Homes & Holiday AG, Börsengang läuft!

Der Ferienimmobilienspezialist geht zur Wachstumsbeschleunigung an die Börse. Die Zeichnungsfrist für die Homes & Holiday-Aktie (DE000A2GS5M9) läuft noch bis zum 21. Juni, Zeichnungen sind möglich per Kauforder am Börsenplatz München zu einem Preis von 2,50 €. Die Positionierung in Europas attraktivsten Ferienimmobilienregionen ist hervorragend. In Mallorca ist die Tochtergesellschaft Porta Mallorquina unter den TOP-3-Maklerhäusern, der Fokus des weiteren Wachstum liegt auf Standorten in Spanien und Deutschland. Dort befinden sich die Preise im starken Aufwärtstrend. Unser Research sieht den fairen Wert nach IPO bei 4,83 € je Aktie und damit eine hohe Kurschance.

News im Fokus

Daimler AG: Daimler passt Ergebnis-Erwartungen an

20. Juni 2018, 22:05

Aktuelle Research-Studie

artec technologies AG

Original-Research: artec technologies AG (von GBC AG): Kaufen

20. Juni 2018